AI Consensus Investment Thesis
Boston Scientific (BSX) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
STRONG BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
STRONG BUY$53
+21.4%5-Year
STRONG BUY$97
+123.1%Latest flagship insight
Procedural Moats and Vascular Scale Drive Cash Recovery Beyond Disruption
Sharp divergence characterizes market sentiment between short-term electrophysiology share losses post-cyberattack and enduring procedural cash flows. High consensus affirms that non-discretionary cardiovascular demand and the Penumbra integration support cash-flow recovery, while competitive catheter pricing and elevated acquisition leverage remain primary structural frictions.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Ray Dalio (Strategist), Machiavelli (Insider), Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Warren Buffett (Value Purist), Superintelligence (Anthropologist), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Boston Scientific at the forecast anchor (2026-09-18): $22,312 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 44.93 | +3.66% | +3.66% | Third-quarter financial disclosures reveal cyber disruption remediation costs and delayed shipments, offset by baseline procedure resilience. Investors establish an initial valuation floor as supply-chain restoration commences and Penumbra merger financing terms gain clarity. |
| Q1 2027 | 47.71 | +6.20% | +10.09% | Fourth-quarter results show aggressive order catch-up, clearing deferred catheter backlogs. Conservative full-year guidance confirms 2027 as a foundational transition year, relieving catastrophic fears and encouraging institutional accumulation from trough multiples. |
| Q2 2027 | 50.25 | +5.33% | +15.95% | Penumbra acquisition closes, expanding peripheral thrombectomy procedural scale. Cross-selling synergies across international cath labs begin materializing, cushioning near-term debt service expenses and initial electrophysiology pricing competition from rival platforms. |
| Q3 2027 | 52.63 | +4.73% | +21.44% | Initial operational restructuring efficiencies generate overhead savings, stabilizing operating margins above 20%. Sustained procedure volumes across endoscopy and interventional cardiology counterbalance competitive pricing pressure in domestic pulsed-field ablation accounts. |
| Q4 2027 | 55.48 | +5.42% | +28.02% | Year-end procedural volume catch-up accelerates operating cash flows. Management directs surplus liquidity toward initial debt retirement, easing credit spread concerns and supporting modest equity multiple recovery as structural heart referrals stabilize. |
| Q1 2028 | 58.55 | +5.53% | +35.10% | Commercial rollout of next-generation electrophysiology catheters and intravascular lithotripsy commences. Demonstrable clinical workflow improvements stem domestic market share losses, prompting positive earnings revisions across institutional research models. |
| Q2 2028 | 61.50 | +5.03% | +41.90% | Accelerating thrombectomy adoption across European and Asian hospitals drives accretive top-line contribution. Expanding manufacturing automation defends consolidated gross margins, enabling consistent free-cash-flow conversion despite elevated sovereign bond yields. |
| Q3 2028 | 63.55 | +3.34% | +46.64% | Cyclical hospital procurement reviews and competitive ablation bundling introduce temporary average selling price friction. However, non-discretionary procedure volumes across core cardiovascular lines cushion consolidated revenue, limiting valuation pullbacks. |
| Q4 2028 | 66.64 | +4.86% | +53.76% | Full-year free cash flow surpasses $4.2 billion, validating post-merger cash generation. Deleveraging milestone targets are achieved ahead of schedule, reducing financial risk discounts and encouraging steady long-term institutional accumulation. |
| Q1 2029 | 69.67 | +4.55% | +60.76% | Enterprise restructuring program delivers over half of targeted $500 million run-rate savings. Operating leverage widens operating margins, driving high-single-digit per-share earnings growth that offsets higher debt refinancing coupons. |
| Q2 2029 | 72.43 | +3.96% | +67.12% | International commercial penetration in Japan and emerging markets delivers double-digit procedural expansion. Broader procedural diversification insulates the franchise from mature domestic catheter price competition, supporting sustained equity compounding. |
| Q3 2029 | 75.22 | +3.85% | +73.56% | Thrombectomy cross-selling maturity and advanced imaging integration enhance hospital account retention. Incremental operating efficiencies drop directly to free cash flow, sustaining positive equity momentum through defensive medical device demand. |
| Q4 2029 | 78.15 | +3.90% | +80.33% | Full achievement of enterprise restructuring savings expands normalized operating margins past 22%. Net debt to EBITDA approaches normalized targets, enabling management to reactivate disciplined share repurchases. |
| Q1 2030 | 81.16 | +3.85% | +87.27% | Audited fiscal results demonstrate robust return on invested capital and durable cash conversion. Reduced share count and lower interest expense amplify per-share earnings growth, reinforcing multi-year multiple normalization. |
| Q2 2030 | 83.70 | +3.13% | +93.13% | Mature clinical adoption across pulsed-field ablation and left-atrial-appendage closure yields highly predictable consumable reorder streams. Consistent cash collection insulates operating returns from broader late-cycle macroeconomic deceleration. |
| Q3 2030 | 85.65 | +2.32% | +97.61% | Hospital procurement committees tighten capital budgets, moderately dampening new console placements. Resilient single-use disposable catheter utilization protects operating income, preserving steady baseline cash flows despite modest multiple compression. |
| Q4 2030 | 88.63 | +3.49% | +104.51% | Seasonal elective procedural catch-up and disciplined operating expense controls drive strong fourth-quarter cash generation. Surplus free cash flow fuels continued debt reduction, cementing an investment-grade balance sheet profile. |
| Q1 2031 | 91.44 | +3.16% | +110.97% | Annual guidance confirms a diversified, high-cash-flow medical technology leader compounding at mid-single digits organically. Consistent operating margin resilience above 22% supports fair valuation multiples reflective of high-barrier medtech peers. |
| Q2 2031 | 94.10 | +2.92% | +117.13% | Next-generation peripheral vascular and structural heart pipelines enter clinical deployment, defending category relevance. Expanding international procedural volumes offset mature domestic market growth, maintaining dependable top-line momentum. |
| Q3 2031 | 96.70 | +2.76% | +123.12% | The five-year recovery arc concludes with normalized operating earnings and strong cash yields fully established. Valuation settles around historical medtech medians, delivering substantial total shareholder return from 2026 trough capitulation. |
The investment case balances an acute valuation contraction against the underlying compounding power of an essential medical device portfolio. Following successive guidance cuts and temporary cyber disruption, market pricing discounts permanent impairmentpermanent impairmentA lasting loss in the value of an investment that is unlikely to recover.View full glossary entry across electrophysiology and left-atrial-appendage franchises. However, approximately 75% of operations continue compounding organically near 6%, supported by $3.62 billion in trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. Integrating Penumbra secures vascular thrombectomy leadership, while a $500 million restructuring program defenses operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward 22%. Valuation sensitivity centers on post-acquisition balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry absorption. Deploying $11 billion in new debt into a 5% sovereign yield curveyield curveThe relationship between interest rates and the maturity of debt securities.View full glossary entry elevates interest expense, restricting capital returnscapital returnsDistributions of capital to investors, commonly through dividends or share repurchases.View full glossary entry and near-term multiple re-expansion. The strongest counterargument highlights irreversible pulsed-field ablation share losses to well-capitalized conglomerates.
Key insights
- Secular demographic volume growth in cardiovascular procedures provides non-discretionary demand that permanently decouples operational cash flows from broader macroeconomic interest-rate volatility.
- Penumbra platform consolidation diversifies procedural exposure away from contested cardiac lines, establishing high-margin clinical chokepoints across neurovascular and peripheral interventions.
- Post-merger deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry and structural restructuring capture will drive per-share owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry growth far faster than headline top-line expansion implies.
Recent stock declines reflect panic over shipping delays and catheter competition rather than a broken business. The company still generates over $3.6 billion in annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, backed by essential heart, endoscopy, and urology devices that doctors use daily. Adding Penumbra creates a vascular powerhouse, while operational cost cuts protect profits. Even with higher borrowing costs, reliable patient demand ensures steady multi-year financial recovery.
Key insights
- Non-elective heart and vascular procedures cannot be postponed, guaranteeing consistent hospital demand through economic ups and downs.
- Acquiring Penumbra establishes market leadership in blood clot removal, reducing reliance on any single cardiac device line.
- Consistent debt repayment using robust operational cash flow will steadily rebuild investor confidence and expand per-share profits.
Deep Dive
Prevailing market sentiment treats the enterprise as a fallen growth story whose competitive advantage has evaporated. Analysts focus on decelerating electrophysiology momentum, intensifying competition from conglomerates, standalone Watchman referral plateaus, and cyberattack disruptions. The crowd assumes high-growth compounding is finished, pricing the equity at a trough multiple of 17.5 times trailing earnings.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market sentiment treats the enterprise as a fallen growth story whose competitive advantage has evaporated. Analysts focus on decelerating electrophysiology momentum, intensifying competition from conglomerates, standalone Watchman referral plateaus, and cyberattack disruptions. The crowd assumes high-growth compounding is finished, pricing the equity at a trough multiple of 17.5 times trailing earnings.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially underestimates intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry, causing severe underpricing. The market mistakenly conflates temporary cyber disruptions and category normalization in two specific franchises with permanent corporate impairment. It overlooks that 75% of revenues compound steadily at 6% with 70% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, supported by $3.62 billion in free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. The strongest challenge is sustained catheter price competition, yet non-discretionary procedural volume creates an unpriced margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? A sequence of clean financial prints demonstrating normalized order shipping and stabilizing electrophysiology market share through early 2027 will shatter the broken-growth narrative. Repricing will gain decisive momentum as Penumbra thrombectomy sales consolidate, proving that procedural backlogsbacklogThe total value of signed contracts yet to be fulfilled, representing future revenue visibility.View full glossary entry were deferred rather than permanently lost and forcing sell-side earnings revisions.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Capitulation
Sentiment indicators exhibit strong consensus on deep cyclical fear and capitulation. Disagreement centers on whether electrophysiology competition represents permanent market-share erosion or normal multi-vendor stabilization, directly dictating whether the subsequent cycle phase becomes rapid recovery or extended consolidation.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of 3.75% to 4.00% policy rates and 5% Treasury yields creates moderate headwinds for hospital capital budgets and acquisition debt service. However, non-discretionary cardiovascular demand exhibits low economic sensitivity, enabling 70% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and $3.6 billion in cash flow to outpace medical inflation.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement centers on the durability of electrophysiology growth and the valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry applied to normalized cash flows. Bullish analyses argue that Farapulse retains an unassailable clinical moat and model swift multiple re-expansion to 24x earnings as next-generation catheters launch. Conversely, cautious perspectives demonstrate that rival pulsed-field ablation platforms are causing irreversible market-share dilution, while $11 billion in acquisition debt will constrain per-share earnings growth. Observing whether domestic electrophysiology sales stabilize above 6% organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry across upcoming quarterly prints will determine whether the thesis becomes an earnings compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry or a valuation-capped recovery.
Base-Case Forces
Event Risk ScoreModerate40/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Penumbra Vascular Platform Absorption | Competitive Positioning | +28% | +24% | Integrating Penumbra's market-leading mechanical thrombectomy and neurovascular portfolios injects a scaled, high-margin growth engine. Cross-selling through global commercial channels captures hospital cath-lab call points, adding over $1.5 billion in accretive cardiovascular revenue and expanding enterprise procedural breadth over the forecast horizon. |
| Non-Electrophysiology Franchise Compounding | Competitive Positioning | +24% | +20% | Three-quarters of the portfolio outside electrophysiology—including Interventional Cardiology, Endoscopy, and Urology—continues compounding organically at 6% to 7%. Underwritten by non-discretionary clinical demand, this diversified base reliably generates over $3.6 billion in free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, anchoring corporate earning power. |
| Next-Generation Catheter Innovation Cycle | Innovation And Product | +22% | +18% | Launching next-generation pulsed-field ablation catheters, integrated intracardiac echocardiography, and intravascular lithotripsy counters competing entrants. Enhanced procedural efficiency and clinical workflow integration defend catheter realization rates, stabilizing electrophysiology division revenue growth above high single digits through mid-term adoption. |
| Enterprise Operational Restructuring Harvest | Operational Efficiency | +18% | +16% | A multi-year operational efficiencyoperational efficiencyThe ability to produce an intended output or service with minimal waste, delay, or cost.View full glossary entry initiative targets $500 million in structural annualized cost savings by exiting 2029, with over half captured by 2027. Streamlining global administrative overhead and automating precision manufacturing expands operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward 22%, directly compounding per-share owner cash flows. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Intensifying Pulsed-Field Catheter Competition | Competitive Positioning | -18% | -15% | Aggressive commercial rollouts of competing pulsed-field ablation catheters by Medtronic and Johnson & Johnson erode early monopoly market share toward 50%. Multi-vendor hospital purchasing contracts force price concessions on mapping and catheters, permanently compressing division growth from historical peaks. |
| Acquisition Leverage Financing Drag | Capital Allocation | -14% | -12% | Funding the $14.5 billion Penumbra transaction requires approximately $11 billion in new borrowing amid 5% Treasury yields, adding substantial annual interest expense. Elevated debt service absorbs operating cash flows, restricting near-term discretionary share repurchases until balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry targets are achieved. |
| Structural Heart Referral Deceleration | Sector And Industry | -12% | -10% | Standalone left-atrial-appendage closure growth decelerated to single digits as cardiologists adjust referral criteria toward concomitant procedures following recent trial interpretations. Slower volume expansion across high-margin Watchman implants removes a primary historical growth engine, capping corporate gross margin expansiongross margin expansionAn increase in gross profit as a percentage of revenue.View full glossary entry. |
| Hospital Procurement Budget Constraints | Macroeconomic And Macrofinancial | -9.0% | -8.0% | Elevated healthcare labor costs and restrictive reimbursement updates squeeze hospital operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry globally. Value-based procurement committees scrutinize premium medical device pricing and lengthen capital equipment purchasing cycles, moderating console placement velocity and single-use catheter reorder momentum. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Catastrophic Electrophysiology Safety Recall | 18% | -32% | An unexpected post-market clinical safety signal or severe tissue complication involving pulsed-field ablation catheters could prompt urgent FDA warning letters or commercial holds by 2027. Halting catheter shipments would forfeit market leadership to waiting competitors, trigger material litigation liabilities, and eliminate hundreds of millions in operating profit. |
| Antitrust Injunction Against Penumbra | 20% | -20% | Antitrust litigation by the Federal Trade Commission or European regulators challenging the $14.5 billion Penumbra transaction on vascular monopoly grounds could block the acquisition in late 2026. Deal termination would trigger heavy breakup fees, forfeiting entry into mechanical thrombectomy and stranding capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry strategy. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| CHAMPION First-Line Indication Approval | 32% | +32% | Extended clinical trial readouts establishing Watchman FLX superiority over direct oral anticoagulants in broad non-valvular atrial fibrillation cohorts could trigger FDA first-line label expansion by 2028. Moving from secondary contraindication therapy to primary prevention would quadruple the addressable patient population, injecting over $1 billion in high-margin revenue. |
| Accelerated Thrombectomy Synergies Realization | 28% | +24% | Consolidating Penumbra's computer-assisted vacuum thrombectomy platforms through established multinational distribution channels could outpace modeled cross-selling projections by 30%. Rapid procedural adoption across European and Asian surgical centers by 2028 would generate substantial unexpected operating income, accelerating corporate debt retirement and multiple rerating. |
Company Financial Analysis
Boston Scientific Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Boston Scientific delivered strong revenue of $20.1 billion in fiscal 2025, surging nearly 20% year-over-year as its pioneering heart ablation systems gained rapid global adoption. However, growth slowed to 7.5% in the second quarter of 2026 as competing device makers launched rival systems and an August computer outage briefly disrupted factory shipments. This headline slowdown led management to trim full-year organic growth guidance to around 5% to 6%. Crucially, this deceleration represents a transition toward steady cash generation rather than corporate decay. Trailing twelve-month free cash flow reached a formidable $3.62 billion, proving that patient care generates dependable cash regardless of quarterly noise. Because scheduled cardiovascular procedures are deferred rather than canceled, cleared shipping backlogs will restore recognized earnings into 2027.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 20.1B | USD 2.9B | USD 3.7B |
| 2024 | USD 16.7B | USD 1.9B | USD 2.6B |
| 2023 | USD 14.2B | USD 1.6B | USD 1.7B |
| 2022 | USD 12.7B | USD 698M | USD 914M |
| 2021 | USD 11.9B | USD 1B | USD 1.3B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 49.4x | TTM | Native | USD / USD |
| 2024 | 71.8x | TTM | Native | USD / USD |
| 2023 | 53.6x | TTM | Native | USD / USD |
| 2022 | 95.6x | Annual | Native | USD / USD |
| 2021 | 58.7x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profit margins widened significantly in fiscal 2025, with gross margins climbing to 69% and operating margins reaching nearly 20%. This profitability surge occurred because premium heart implants and specialty catheters carry strong pricing power and cost very little to produce once manufacturing reaches scale. High-margin procedure volume dropped directly to the bottom line. While competitor discounting in electrophysiology and temporary cyber recovery expenses will flatten near-term margins, long-term profitability remains well protected. An enterprise restructuring plan targeting $500 million in annual overhead savings by 2029 will counterbalance pricing pressures. As higher-margin vascular products integrate into global sales channels, operating margins should sustainably stabilize above 22%. over time.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 4B | 19.8% | 14.4% |
| 2024 | USD 2.6B | 15.7% | 11.1% |
| 2023 | USD 2.2B | 15.3% | 11.2% |
| 2022 | USD 1.8B | 14.4% | 5.5% |
| 2021 | USD 1.9B | 16.2% | 8.7% |
Balance sheet and leverage
AI Review
The company entered 2026 with a solid financial foundation, supported by $24.2 billion in shareholder equity and a low debt-to-equity ratio of 0.51. Operating earnings covered annual interest payments more than ten times over, providing absolute protection against everyday financial turbulence. Strong cash generation gives the company substantial flexibility to navigate volatile market environments. The critical test ahead involves absorbing the pending $14.5 billion Penumbra purchase, which requires approximately $11 billion in new borrowing. While this debt will temporarily increase balance sheet leverage during a period of higher interest rates, more than $3.6 billion in annual free cash flow provides sufficient firepower to pay down debt rapidly without threatening financial stability.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 12.4B | USD 2B | USD 10.4B net debt | 1.62x |
| 2024 | USD 11.1B | USD 414M | USD 10.7B net debt | 1.08x |
| 2023 | USD 9.5B | USD 865M | USD 8.6B net debt | 1.32x |
| 2022 | USD 9.3B | USD 928M | USD 8.4B net debt | 1.51x |
| 2021 | USD 9.5B | USD 1.9B | USD 7.5B net debt | 1.48x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management maintains a disciplined capital footprint, spending just 4.4% of revenue on physical buildings and factory equipment in fiscal 2025. Instead of constructing expensive real estate, the company directs capital toward product engineering and clinical trials, investing over $2.05 billion directly into research and development. This focused spending protects high-margin product designs and automates cleanroom catheter assembly. The real investment story lies in strategic acquisitions. Committing $14.5 billion for Penumbra and $1.5 billion for heart valve specialist MiRus allows the business to buy proven, fast-growing medical technologies rather than building them from scratch. This strategy commits substantial upfront capital but quickly opens major new hospital markets.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 876M | USD 2.1B |
| 2024 | USD 790M | USD 1.6B |
| 2023 | USD 800M | USD 1.4B |
| 2022 | USD 612M | USD 1.3B |
| 2021 | USD 554M | USD 1.2B |
Quarterly Forecast Scenarios
Boston Scientific Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $39.87 | $45.26 | $48.11 | $750.26 | |
| $43.06 | $48.11 | $51.96 | $736.44 | |
| $45.03 | $50.66 | $55.07 | $743.40 | |
| $45.93 | $53.13 | $57.33 | $755.15 | |
| $47.77 | $56.11 | $60.19 | $776.22 | |
| $50.16 | $59.29 | $64.42 | $787.13 | |
| $52.17 | $62.33 | $68.93 | $802.83 | |
| $52.70 | $64.80 | $73.06 | $812.05 | |
| $55.33 | $67.98 | $77.45 | $839.18 | |
| $57.54 | $71.16 | $81.32 | $850.50 | |
| $59.84 | $74.04 | $85.38 | $872.39 | |
| $61.06 | $77.05 | $89.65 | $885.51 | |
| $62.89 | $80.06 | $93.24 | $909.56 | |
| $64.77 | $83.30 | $97.88 | $916.13 | |
| $66.07 | $85.96 | $101.80 | $936.51 | |
| $65.29 | $88.50 | $105.87 | $947.34 | |
| $67.90 | $91.55 | $110.11 | $969.59 | |
| $69.94 | $94.62 | $115.61 | $979.99 | |
| $72.04 | $97.41 | $119.08 | $999.60 | |
| $73.66 | $100.12 | $122.65 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported consensus pattern confirms that approximately 75% of operations outside electrophysiology and structural heart continue compounding steadily at 6% to 7% organically, generating over $3.6 billion in trailing free cash flow. Correlated assumptions across bullish reports inappropriately extrapolate rapid valuation rerating back to 25x earnings while understating the friction of funding the $14.5 billion Penumbra transaction in a 5% interest-rate regime. The strongest contrarian case establishes that electrophysiology market share erosion from rival pulsed-field ablation entrants and slowed standalone left-atrial-appendage referrals represent permanent structural adjustments rather than temporary blips. Unsupported claims regarding frictionless commercial synergy and immediate multiple recovery were heavily downweighted. Unresolved uncertainties include post-cyberattack customer retention, final antitrust closing conditions, and integration leverage. These findings assign primary weight to rigorously documented, cash-flow-grounded reports that model deliberate margin recovery while penalizing unevidenced multiple expansion.
Universal Investor AI
The Polymath
GPT-6 AstraThis analysis provides exceptional primary evidence regarding post-cyber recovery filings, SEC disclosures, and conservative capital constraints. Its cautious cash-flow compounding scenario captures realistic margin pressures and Penumbra debt friction without overstating immediate multiple expansion, offering sound causal consistency and independent analytical balance.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashStrong macroeconomic grounding and thorough appraisal of the non-electrophysiology portfolio justify this allocation. The report accurately evaluates the 5% Treasury yield backdrop, debt service requirements for Penumbra, and realistic operational restructuring timelines, presenting a balanced and causal long-term pathway.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashFeaturing detailed evidentiary sourcing on cyberattack resolution and FDA access-system corrections, this report provides deep operational clarity. It accurately balances steady compounding across 75% of operations against realistic electrophysiology share loss and Penumbra integration burdens.
Michael Burry AI
The Vulture
Gemini 3.8 FlashThis viewpoint offers rigorous forensic skepticism, correctly identifying deferred versus destroyed procedural revenues post-cyberattack and parsing pro-forma leverage risks. Its prudent multiple expansion assumptions and emphasis on cash conversion yield a well-reasoned contrarian margin of safety.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashGrounding its view in durable owner earnings and capital discipline, this report effectively analyzes the 5.6% free-cash-flow yield and share retirements. It balances competitive ablation erosion against broad-based interventional compounding, providing high causal consistency and disciplined valuation metrics.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThis submission offers a well-documented analysis of the 2026 guidance cuts, enterprise restructuring initiatives, and upcoming 2027 product launches. Its thesis logically bridges short-term operational capitulation to mid-term cash-flow normalization, supported by solid financial evidence.
Universal Investor AI
The Polymath
Opus 5With exhaustive primary documentation on SEC filings, Class I recall corrections, and antitrust timelines, this perspective provides exceptional factual grounding. Its sober recognition of guidance credibility deficits and realistic 15x exit valuation anchors the consensus path.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThe evaluation details institutional hospital inertia, CMS inpatient reimbursement moats, and operational restructuring savings effectively. However, it underweights post-acquisition leverage under restrictive monetary policy and assumes swift multiple expansion, meriting a moderate weight reflecting solid regulatory and commercial insights.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThis thesis presents compelling demographic framing and procedural stickiness arguments but suffers from philosophical abstraction rather than detailed balance sheet scrutiny. It underestimates acquisition financing friction and competitive catheter pricing dynamics, justifying a modest weighting grounded in structural procedural demand.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThe report highlights technological paradigm shifts in pulsed-field ablation and procedural velocity, but relies on overly rapid multiple recovery assumptions. It downplays prolonged customer contract friction and antitrust review risk, warranting a measured allocation focused on technological hardware moats.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThe assessment demonstrates sound understanding of clinical training inertia, high switching costs, and non-deferrable procedure volumes. However, it projects optimistic operating margin expansion without fully penalizing the capital allocation drag of pending merger debt, warranting a moderate weight.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashThe perspective relies heavily on aggressive operational turnaround assumptions, projecting rapid margin expansion to 25x earnings while dismissing intense pulsed-field ablation competition. While vascular cross-selling arguments are directionally viable, lack of citation rigor and excessive near-term optimism limit its overall portfolio weighting.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashWhile correctly identifying inelastic clinical demand and strong underlying gross margins, the analysis minimizes credible multi-source pulsed-field ablation competition from large conglomerates. Its aggressive multiple rerating scenario lacks grounding in near-term cash deployment realities, warranting a lower allocation.
Universal Investor AI
The Polymath
Gemini 3.8 FlashWhile correctly identifying structural heart clinical durability, the report largely ignores the multi-billion-dollar financing and integration headwinds of the Penumbra acquisition. Its assumption of rapid, frictionless multiple rerating without addressing debt drag warrants a minimal weighting.
Research Provenance
References & Context
This Boston Scientific consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 116 deduplicated sources retained for this batch.
- 01Vascular Access Systems Correction: Boston Scientific Updates Use Instructions for WATCHMAN Access Systems | FDAfda.gov
- 02BOSTON SCIENTIFIC CORP - Form 425 - FY2026sec.gov
- 03BOSTON SCIENTIFIC CORP - Form 8-K - FY2026sec.gov
- 04bsx-20260907sec.gov
- 05https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/q22026earningsrelease.htm?utm_source=openaisec.gov
- 06FDA issues most serious recall for certain pacemaker devices by Boston Scientific | AHA Newsaha.org
- 07Boston Scientific (BSX) Q2 2026 Earnings Call Transcript - AOLaol.com
- 08Understand the CHAMPION-AF LAAC vs NOACs trial results - Boston Scientificbostonscientific.com
- 09Boston Scientific to acquire Penumbra for $14.5Bcardiovascularbusiness.com
- 10Steerable sheaths for PFA recalled due to safety riskcardiovascularbusiness.com
- 11BSX Stock Quote Price and Forecast | CNNcnn.com
- 12Boston Scientific cuts guidance again after unveiling restructuring planfiercebiotech.com
- 13Boston Scientific again cuts 2026 guidancefinance.yahoo.com
- 14Boston Scientific Corporation (BSX) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
- 15Boston Scientific trims annual profit forecast on softer Watchman device demand By Reutersinvesting.com
And 101 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.